~~<i id='D9E527F4A9'><strike id='D9E527F4A9'><tt id='D9E527F4A9'><pre id='D9E527F4A9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：hotspot 2025-09-28 18:31:07 - browse：8

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

entertainment

knowledge

entertainment

focus

entertainment

Wikipedia

OrgandonationpaperworkatMid-AmericaTransplantServicesinSt.Louis.WhitneyCurtis/APTheUnitedStateshadao

WSS

HIPAA doesn't protect reproductive records from prosecutors

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

As Taiwan prepares for anti

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Drug repurposing or repositioning? The language matters

Virginia high school admissions case could be legal follow

entertainment

focus

entertainment

Cancer drug shortages should be causing more outrage

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

23andMe had bad news about my health. I wish a person had delivered it

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Bright Health sells Medicare Advantage business to Molina

Medicare proposal to cover medical devices draws a mixed reaction

Heart attack and stroke risk calculators need revising

Sports medicine is finally prioritizing gender equality

Guidelines to prevent youth baseball injuries need more muscle

Psychedelics group wrestles with new pharma identity

knowledge

Artificial intelligence advances fuel industry trying to preserve loved ones after death

In age of alternative facts, a scholarly course on calling out crap

Review: 'Barbie' will hit you like a shot in the heart

7 of the most gruesome medical devices in history

How one medical school became remarkably diverse

In new study, freeze

entertainment

focus

entertainment

Wikipedia